ANI Pharmaceuticals Inc (ANIP) 25.55 $ANIP
Transition Therapeutics (TTHI) Jumps: Stock Up 11.5% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Apr 17, 7:51AM CDT
Transition Therapeutics Inc. was a big mover last session, as its shares rose nearly 12% on the day.
ImmunoGen, Inc. (IMGN) in Focus: Stock Rallies 11% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Apr 17, 7:44AM CDT
ImmunoGen, Inc. was a big mover last session, as the company saw its shares surge 11% on the day.
Kythera Biopharmaceuticals, Inc. (KYTH) in Focus: Stock Surges 9.9 % - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Apr 16, 7:44AM CDT
Kythera Biopharmaceuticals, Inc. was a big mover last session, as the company saw its shares rise nearly 10% on the day.
Amicus Therapeutics (FOLD) Crumbles: Stock Falls by 8% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Apr 16, 7:33AM CDT
Amicus has not seen any positive earnings estimate revisions for the current quarter along with a significant decline in its share price for the past month
Global Female Sexual Dysfunction therapeutics Pipeline Review 2014: Analysis of 6 Companies and 11 Drug Profiles
M2 - Tue Apr 15, 6:00AM CDT
Research and Markets (http://www.researchandmarkets.com/research/kb4tcq/female_sexual) has announced the addition of the "Female Sexual Dysfunction - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Female Sexual Dysfunction, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Female Sexual Dysfunction and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Scope - The report provides a snapshot of the global therapeutic landscape of Female Sexual Dysfunction - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Female Sexual Dysfunction and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Female Sexual Dysfunction products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Female Sexual Dysfunction pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Female Sexual Dysfunction - Companies Involved in Therapeutics Development - Palatin Technologies, Inc. - M et P Pharma AG - ANI Pharmaceuticals, Inc. - Fabre-Kramer Pharmaceuticals, Inc. - EndoCeutics, Inc. - S1 Biopharma, Inc. Drug Profiles - testosterone - prasterone - TGWOO-AA - bremelanotide - TBS-2 - (bupropion trazodone hydrochloride) - TBS-2 - PL-6983 - S1B-307 - S1B-3006 - Next Generation Melanocortin Receptor Specific Peptide For more information visit http://www.researchandmarkets.com/research/kb...ale_sexual
Valuation Doesn't Equal Share Price (and That Goes Double for Biotech)
Brian Orelli, The Motley Fool - Motley Fool - Mon Apr 14, 6:52PM CDT
Most investors realize that share price is meaningless when comparing companies. A company at $50 per share might actually be worth more than a company at $100 per share because a company's value is determined by the number of outstanding shares in...
Qiagen Expands Personalized Healthcare Pipeline - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Apr 11, 2:20PM CDT
Qiagen acquires an exclusive worldwide license for the calreticulin (CALR) biomarker from CeMM Vienna.
Rite Aid (RAD) Jumps: Stock Up 8.4% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Apr 11, 8:39AM CDT
Rite Aid Corporation was a big mover last session, as its shares rose over 8% on the day.
Gilead Sciences (GILD) Falls: Stock Goes Down 7.3% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Apr 11, 8:00AM CDT
Gilead Sciences saw a big move last session, as the company’s shares fell by over 7% on the day.
Celladon (CLDN) Jumps: Stock Up 11.5% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Apr 11, 7:51AM CDT
Celladon Corporation was a big mover last session, as its shares rose nearly 12% on the day.
Baxano Surgical, Inc. (BAXS) in Focus: Stock up 10.7% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Apr 11, 7:44AM CDT
Baxano Surgical, Inc. was a big mover last session, as the company saw its shares rise nearly 11% on the day.
Enzymotec Ltd. (ENZY) in Focus: Stock Rallies 11.06% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Apr 10, 7:44AM CDT
Enzymotec Ltd. was a big mover last session, as the company saw its shares rise a little over 11% on the day.
RadNet, Inc. (RDNT) in Focus: Stock Surges 9.8% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Apr 09, 7:44AM CDT
RadNet, Inc. was a big mover last session, as the company saw its shares rise nearly 10% on the day.
RadNet Touches New 52-Week High - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Apr 08, 9:26AM CDT
RadNet's adjusted earnings per share beat the Zacks Consensus Estimate by 8 cents.
Idenix Pharmaceuticals (IDIX) Jumps: Stock Up 12.4% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Apr 08, 7:51AM CDT
Idenix Pharmaceuticals Inc. was a big mover last session, as its shares rose over 12% on the day.
Puma Biotechnology (PBYI) in Focus: Stock Tumbles 18.3% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Apr 08, 7:45AM CDT
Puma Biotechnology has seen negative consensus estimates for the current quarter along with a significant decline in its share price for the past month
Questcor Pharmaceuticals (QCOR) Shows Strength: Stock Surges 18.7% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Apr 08, 7:44AM CDT
Questcor Pharmaceuticals, Inc. was a big mover last session, as the company saw its shares shoot up nearly 19% on the day.
Response Genetics (RGDX) in Focus: Stock Up 18.3% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Apr 04, 8:39AM CDT
Response Genetics, Inc was a big mover last session, as its shares rose over 18% on the day.
Acceleron Pharma (XLRN) Jumps: Stock Up 13.2% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Apr 03, 8:39AM CDT
Acceleron Pharma, Inc. was a big mover last session, as its shares rose over 13% on the day.
RadNet (RDNT) in Focus: Stock Adds 11.8% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Apr 03, 7:51AM CDT
RadNet, Inc. was a big mover last session, as its shares rose nearly 12% on the day.
Transition Therapeutics (TTHI) Jumps: Stock Up 11.5% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Apr 17, 7:51AM CDT
Transition Therapeutics Inc. was a big mover last session, as its shares rose nearly 12% on the day.
ImmunoGen, Inc. (IMGN) in Focus: Stock Rallies 11% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Apr 17, 7:44AM CDT
ImmunoGen, Inc. was a big mover last session, as the company saw its shares surge 11% on the day.
Kythera Biopharmaceuticals, Inc. (KYTH) in Focus: Stock Surges 9.9 % - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Apr 16, 7:44AM CDT
Kythera Biopharmaceuticals, Inc. was a big mover last session, as the company saw its shares rise nearly 10% on the day.
Amicus Therapeutics (FOLD) Crumbles: Stock Falls by 8% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Apr 16, 7:33AM CDT
Amicus has not seen any positive earnings estimate revisions for the current quarter along with a significant decline in its share price for the past month
Global Female Sexual Dysfunction therapeutics Pipeline Review 2014: Analysis of 6 Companies and 11 Drug Profiles
M2 - Tue Apr 15, 6:00AM CDT
Research and Markets (http://www.researchandmarkets.com/research/kb4tcq/female_sexual) has announced the addition of the "Female Sexual Dysfunction - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Female Sexual Dysfunction, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Female Sexual Dysfunction and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Scope - The report provides a snapshot of the global therapeutic landscape of Female Sexual Dysfunction - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Female Sexual Dysfunction and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Female Sexual Dysfunction products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Female Sexual Dysfunction pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Female Sexual Dysfunction - Companies Involved in Therapeutics Development - Palatin Technologies, Inc. - M et P Pharma AG - ANI Pharmaceuticals, Inc. - Fabre-Kramer Pharmaceuticals, Inc. - EndoCeutics, Inc. - S1 Biopharma, Inc. Drug Profiles - testosterone - prasterone - TGWOO-AA - bremelanotide - TBS-2 - (bupropion trazodone hydrochloride) - TBS-2 - PL-6983 - S1B-307 - S1B-3006 - Next Generation Melanocortin Receptor Specific Peptide For more information visit http://www.researchandmarkets.com/research/kb...ale_sexual
Valuation Doesn't Equal Share Price (and That Goes Double for Biotech)
Brian Orelli, The Motley Fool - Motley Fool - Mon Apr 14, 6:52PM CDT
Most investors realize that share price is meaningless when comparing companies. A company at $50 per share might actually be worth more than a company at $100 per share because a company's value is determined by the number of outstanding shares in...
Qiagen Expands Personalized Healthcare Pipeline - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Apr 11, 2:20PM CDT
Qiagen acquires an exclusive worldwide license for the calreticulin (CALR) biomarker from CeMM Vienna.
Rite Aid (RAD) Jumps: Stock Up 8.4% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Apr 11, 8:39AM CDT
Rite Aid Corporation was a big mover last session, as its shares rose over 8% on the day.
Gilead Sciences (GILD) Falls: Stock Goes Down 7.3% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Apr 11, 8:00AM CDT
Gilead Sciences saw a big move last session, as the company’s shares fell by over 7% on the day.
Celladon (CLDN) Jumps: Stock Up 11.5% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Apr 11, 7:51AM CDT
Celladon Corporation was a big mover last session, as its shares rose nearly 12% on the day.
Baxano Surgical, Inc. (BAXS) in Focus: Stock up 10.7% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Apr 11, 7:44AM CDT
Baxano Surgical, Inc. was a big mover last session, as the company saw its shares rise nearly 11% on the day.
Enzymotec Ltd. (ENZY) in Focus: Stock Rallies 11.06% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Apr 10, 7:44AM CDT
Enzymotec Ltd. was a big mover last session, as the company saw its shares rise a little over 11% on the day.
RadNet, Inc. (RDNT) in Focus: Stock Surges 9.8% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Apr 09, 7:44AM CDT
RadNet, Inc. was a big mover last session, as the company saw its shares rise nearly 10% on the day.
RadNet Touches New 52-Week High - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Apr 08, 9:26AM CDT
RadNet's adjusted earnings per share beat the Zacks Consensus Estimate by 8 cents.
Idenix Pharmaceuticals (IDIX) Jumps: Stock Up 12.4% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Apr 08, 7:51AM CDT
Idenix Pharmaceuticals Inc. was a big mover last session, as its shares rose over 12% on the day.
Puma Biotechnology (PBYI) in Focus: Stock Tumbles 18.3% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Apr 08, 7:45AM CDT
Puma Biotechnology has seen negative consensus estimates for the current quarter along with a significant decline in its share price for the past month
Questcor Pharmaceuticals (QCOR) Shows Strength: Stock Surges 18.7% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Apr 08, 7:44AM CDT
Questcor Pharmaceuticals, Inc. was a big mover last session, as the company saw its shares shoot up nearly 19% on the day.
Response Genetics (RGDX) in Focus: Stock Up 18.3% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Apr 04, 8:39AM CDT
Response Genetics, Inc was a big mover last session, as its shares rose over 18% on the day.
Acceleron Pharma (XLRN) Jumps: Stock Up 13.2% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Apr 03, 8:39AM CDT
Acceleron Pharma, Inc. was a big mover last session, as its shares rose over 13% on the day.
RadNet (RDNT) in Focus: Stock Adds 11.8% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Apr 03, 7:51AM CDT
RadNet, Inc. was a big mover last session, as its shares rose nearly 12% on the day.
